Maine Medicine Weekly Update - 08/12/2019 (Plain Text Version)
|
||
|
In this issue: |
Recent Study Suggests CV Risk Reduction From Continuing Statins After 75
A recent study suggests potential cardiovascular risk reduction associated with continuing statin therapy after the age of 75 years in persons already taking these drugs for primary prevention. However, due to the observational nature of this study, residual confounding cannot be excluded. Future studies, including interventional randomized studies, are needed to confirm these findings and support updating and clarification of guidelines on the use of statins for primary prevention in the elderly.
A recent European study suggests potential cardiovascular risk reduction associated with continuing statin therapy after the age of 75 years in persons already taking these drugs for primary prevention. However, due to the observational nature of this study, residual confounding cannot be excluded. Future studies, including interventional randomized studies, are needed to confirm these findings and support updating and clarification of guidelines on the use of statins for primary prevention in the elderly. The role of statin therapy in primary prevention of cardiovascular disease in persons older than 75 years remains a subject of debate with little evidence to support or exclude the benefit of this treatment. The researchers assessed the effect of statin discontinuation on cardiovascular outcomes in previously adherent 75-year-olds treated for primary prevention. The study itself may be read here: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehz458/5540819 |
|